Table 3.
Preclinical studies with O 6-BG
| Tumor xenograft model | Anticancer drug | Readout | Reference |
|---|---|---|---|
| Medulloblastoma (D341 Med) | Carmustine | Tumour regression | [64] |
| Glioblastoma multiforme (D-456 MG) | |||
| Melanoma (A375P) | TMZ | Tumour growth delay | [65] |
| Gastric adenocarcinoma (BGC-823) | Carmustine | Tumour growth delay | [66] |
| Glioma (SF767) | Carmustine | Tumour growth delay | [67] |
| Glioma (SF767) | Carmustine | Tumour growth delay | [68] |
| Medulloblastoma (D341MED) glioma (D-245 MG) | Carmustine | Tumour growth delay | [69] |
| Pancreatic tumours (MIA PaCa-2, CFPAC-1, PANC-1, CAPAN-2 and BxPC-3) | TMZ or carmustine | Tumour growth delay | [70] |
| Malignant glioma (D-456 MG) | Cyclophosphamide plus carmustine TMZ plus irinotecan | Tumour growth delay | [71] |
| Metastatic neuroblastoma | TMZ plus irinotecan | Prolonged survival | [72] |
| Malignant glioma (F98) | Carmustin | Prolonged survival | [73] |
| Medulloblastoma (Daoy) | Carmustine | Tumour growth delay | [74] |
| Malignant glioma (U87MG) | Carmustine | Tumour growth delay | [75] |
| CNS tumor (D-54M/D-245 MG) | Carmustine | Tumour growth delay | [76] |
| Intracranial malignant glioma (D-456 MG) | Carmustine i.a versus i.p | Prolonged survival | [77] |
| Melanoma | TMZ | Tumour growth delay | [78] |
| Medulloblastoma (Daoy) | Carmustine | Tumour growth delay | [79] |